RA
SOPH icon

Royce & Associates’s SOPHiA GENETICS SOPH Stock Holding History

Royce & Associates’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5M Buy
3,381,736
+1,565,424
+86% +$7.94M 0.16% 214
2026
Q1 		$8.99M Buy
1,816,312
+1,386,055
+322% +$6.74M 0.09% 361
2025
Q4 		$2.01M Buy
+430,257
New +$1.95M 0.02% 588

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $5.12B AUM 19.08% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $369M AUM 45.79% 1-Year Est. Return

Royce & Associates's SOPH Position: Q2 2026 in Review

Royce & Associates increased its SOPHiA GENETICS (SOPH) stake by 86% in Q2 2026, buying an estimated $7.94M and bringing the position to 3,381,736 shares worth $19.5M. The position accounts for 0.16% of the portfolio, ranked #214.

Royce & Associates first reported a position in SOPH in Q4 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold SOPH as of Q2 2026.

  • Royce & Associates held 3,381,736 shares of SOPHiA GENETICS worth $19.5M as of Q2 2026.
  • Royce & Associates bought 1,565,424 SOPHiA GENETICS shares in Q2 2026, an estimated $7.94M.
  • SOPHiA GENETICS made up 0.16% of Royce & Associates's portfolio in Q2 2026, its #214 holding.
  • Royce & Associates first reported a position in SOPHiA GENETICS in Q4 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.